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Dopamine DA2.receptor activation inhibits noradrenaline release in
human kidney slices. Dopamine receptor modulation of noradrenaline
release from renal sympathetic nerves was investigated. Human kidney
slices were incubated with 3H-noradrenaline, placed into superfusion
chambers between two platinum electrodes and field-stimulated at 5
Hz. The slices accumulated radioactivity. Pretreatment of the kidney
slices with 6-hydroxy-dopamine (1.2 mM) prior to the 3H-noradrenaline
incubation reduced the accumulation of radioactivity. The stimulation
induced (S-I) outflow of radioactivity was mainly composed of intact
3H-noradrenaline. The sodium channel blocker tetrodotoxin (I MM),
6-hydroxy-dopamine pretreatment and omission of calcium from the
superfusion solution abolished S-I outflow of radioactivity. The DAr
receptor agonist fenoldopam (SKF 82526; 0.01 and 0.1 M) did not alter
but fenoldopam (1 M) increased S-I outflow of radioactivity. However,
in the presence of either the non-selective a-adrenoceptor antagonist
phentolamine (1 .tM) or the selective a2-adrenoceptor antagonist ida-
zoxan (1 ILM) fenoldopam (1 /LM) had no effect. The DA2-receptor
agonist quinpirole (LY 171555; 1 M) inhibited S-I outflow of radioac-
tivity, an effect blocked by the selective DA2-receptor antagonists
S(-)-sulpiride (10 LM) and domperidone (0.3 /LM) but unaltered either by
the DA1-receptor antagonist SCH 23390 (1 M) or by phentolamine (1
ILM). The a2-adrenoceptor agonist UK 14304 (0.1 LM) inhibited S-I
outflow of radioactivity, and this effect was blocked by phentolamine (1
M) and idazoxan (I j.M) but unaltered by S(-)-sulpiride (10 /LM).
Phentolamine and idazoxan, in contrast to S(-)-sulpiride, domperidone
and SCH 23390, enhanced S-I outflow of radioactivity by themselves.
The DA2-receptor agonist carmoxirole (EMD 45609; 0.03 LM) inhibited
S-I outflow of radioactivity but carmoxirole (0.003 and 0.3 M) did not.
However, in the presence of phentolamine carmoxirole (0.3 and 0.03
M) inhibited S-I outflow of radioactivity to a similar extent. Moreover,
in the presence of idazoxan carmoxirole (0.3 LM) also inhibited S-I
outflow of radioactivity. The inhibitory effect of carmoxirole (0.03 M)
was blocked by S(-)-sulpiride (10 M) but not by SCH 23390(1 SM). The
data suggest that activation of prejunctional DA2-receptors by either
quinpirole or carmoxirole (0.03 .tM) inhibits noradrenaline release in
human kidney cortex. The inhibitory DA2-receptor mediated effect of
carmoxirole (0.3 M) seems to be masked by simultaneous blockade of
prejunctional inhibitory a-autoreceptors, There is no evidence that
activation of DA1-receptors modulates noradrenaline release. Endoge-
nous noradrenaline, in contrast to endogenous dopamine, seems to
activate its respective prejunctional receptor system, since phentol-
amine and idazoxan but neither S(-)-sulpiride nor domperidone en-
hanced S-I outflow of radioactivity.
Renal sympathetic nerve stimulation induces a decrease in
renal blood flow, and an increase in sodium reabsorption and
renin release [1]. The amount of the responsible neurotransmit-
ter noradrenaline released within the kidney is ultimately con-
trolled by the central nervous system via the firing rate of the
renal nerves. However, postganglionic sympathetic nerves pos-
sess prejunctional receptors which when activated can modu-
late the amount of noradrenaline released at the neuroeffector
junction [2—4]. Activation of prejunctional dopamine receptors
inhibits noradrenaline release in rat and rabbit isolated kidney
[5—7] as in many other isolated tissues [8, 9]. Postjunctional
dopamine receptors mediate vasodilatation in vascular beds of
various species [10], including rat and human kidney [11, 12].
These dopamine receptors of the cardiovascular system have
been divided in DA1- and DA2-receptor subtypes on the basis of
structure-activity relationships of several synthetic dopamine
analogues. In general, DA1-receptors are located postjunction-
ally whereas DA2-receptors are located prejunctionally [13, 14].
There may be exceptions. DA2-receptors seem also to be
present in rat glomeruli [15] and rabbit renal [16] and jejunal
arteries [17], in which they have been shown to mediate
inhibition of adenylate cyclase activity and vasodilatation.
However, the hypotensive effect of DA2-receptor agonists in
rats [18, 19] and humans [20] is generally believed to be due to
activation of inhibitory DA2-receptors located on peripheral
sympathetic nerve terminals. Lowering blood pressure via such
a dopaminergic prejunctional mechanism seems to be a reason-
able approach in the treatment of hypertension [21, 221. This
may be especially relevant in the kidney, since an increased
renal sympathetic nerve activity plays a pivotal role in experi-
mental and essential hypertension [23—25]. The operation of
renal prejunctional receptor systems has been studied so far
almost exclusively in experimental animals [26]. The aim of the
present study was to establish an in vitro technique, which
permits investigation of the modulation of noradrenaline release
from human renal sympathetic nerves. Furthermore, prejunc-
tional dopamine receptors were characterized by using selec-
tive DA1- and DA2-receptor agonists and antagonists.
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Human cortical kidney slices
The present in vitro study in human renal cortex was ap-
proved by the local ethics committee. Renal cortex tissue was
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obtained from patients (59.4 2.6 years of age, N = 33)
undergoing renal surgery because of hypernephroma (N = 31),
epithelial carcinoma of the urinary tract (N 1), and metastasis
of a bronchial carcinoma (N 1). Only macroscopically intact
renal cortex tissue was used. None of the patients had been
treated with drugs known to interact with either the storage or
release mechanism of noradrenaline. The renal cortex tissue
was cleared from all connective tissue including the capsule and
cortical slices (0.3 mm thick, diameter 6.5 mm) were prepared.
Experimental design
The cortical kidney slices were incubated with (-)-[2,5,6-3H]-
noradrenaline (42.1 CiImM, 0.5 M) for 60 minutes in Krebs-
Henseleit solution which was continuously bubbled with car-
bogen (95% 02 and 5% C02). The slices were then placed into
six superfusion chambers (volume of 250 1.d) between two
platinum electrodes and were kept in a bath at a temperature of
37°C. The slices were superfused at a constant rate of 1.8
mllmin with Krebs-Henseleit solution for 100 minutes to re-
move loosely bound radioactivity. After 70 minutes of this
washing procedure a priming stimulation (8 Hz, I ms duration,
20 mA, 1 mm) was given. Then, after the washing, 17 consec-
utive samples of the superfusate were collected in three minute
fractions with a fraction collector (Isco Retriever IV, Lincoln,
Nebraska, USA). There were two stimulation periods (27 mm
apart, 20 mA, 5 Hz, 1 ms duration): S1 and S2, 6 and 33 minutes
after commencement of the collections of the superfusate,
respectively. The effect of drugs was tested by adding them to
the superfusion solution 12 minutes before S2. In those exper-
iments in which a drug was present for both stimulation periods
(throughout), it was added to the superfusion solution immedi-
ately after the priming stimulation.
In some experiments the superfusate samples were tested for
their 3H-noradrenaline content by sequential alumina and
Dowex column chromatography [271.
Estimation of radioactivity
A total of 1.8 ml aliquots of the superfusion solution were
mixed with 4 ml scintillation fluid (Picofluor 40, Packard Instru-
ments, Downers Grove, Illinois, USA) to measure the amount
of radioactivity present in the superfusion solution by liquid
scintillation counting. Total tissue radioactivity was determined
at the end of each experiment. The kidney slices were dissolved
in 1 ml tissue solubilizer (Soluene, Packard Instruments) and
then mixed with 4 ml scintillation fluid.
Calculation of results
The spontaneous outflow of radioactivity from the slices was
determined as the mean of the amount of radioactivity in the
superfusate collected during the three-minute collection period
immediately before, and 12 minutes after the onset of stimula-
tion. The stimulation induced (S-I) outflow of radioactivity was
calculated by subtracting the spontaneous outflow of radioac-
tivity from the radioactivity present in the four three-minute
samples collected immediately after the onset of stimulation.
The S-I outflow of radioactivity was subsequently expressed as
a fraction of the total tissue content of radioactivity at the time
of stimulation (fractional S-I outflow of radioactivity). The
fractional S-I outflow of radioactivity in S2 (FR2) is expressed
as a percentage of that in S1 (FR2 as % of FR!). The sponta-
neous (resting) outflow of radioactivity during 2 is expressed
as a percentage of that during S1 (R2 as % of R1). All data are
expressed as mean SEM. Data were analyzed by Student's
unpaired f-test. Probability levels of less than 0.05 were con-
sidered statistically significant.
6-Hydroxv-dopamine pretreatment
Some experiments were performed in kidney slices which
were pretreated with 6-hydroxy-dopamine (1.2 mM) for 10
minutes prior to incubation with 3H-noradrenaline as previously
described for rat caudal artery and portal vein [281. In this case
NaHCO3 and KH2PO4 were omitted from the Krebs-Henseleit
solution. Gluthatione was added to give a final concentration of
20 M. The pH of this solution was between 3.0 and 4.0.
Vehicle control experiments were always run in parallel.
Determination of tissue levels of endogenous noradrenaline
Human kidney cortex was decapsulated, weighed and imme-
diately placed into centrifugation tubes containing perchloric
acid (0.1 pJs4). The slices were homogenized and then centri-
fuged at 10000 r.p.m. for 15 minutes at 4°C. The endogenous
noradrenaline levels were measured in aliquots of the superna-
tant by high-pressure liquid chromatography coupled with
electrochemical detection as described previously [29].
Drugs and vehicles
The Krebs-Henseleit solution had the following composition
(mM/liter): NaCl, 118; KC1, 4.7; CaCI2, 2.5; MgSO4, 0.45;
NaHCO3, 25; KH2PO4, 1.03; D-(+)-glucose, 11.1; disodium
edetate, 0.067; corticosterone, 0.02; ascorbic acid, 0.07.
The following drugs were purchased: Levo-[ring-2 ,5 ,6-3H]nor-
adrenaline (NEN, Dreieich, Germany). Tetrodotoxin and cor-
ticosterone (Sigma Chemical Co., St. Louis, Missouri, USA).
Phentolamine mesylate (Ciba-Geigy, Wehr, Germany). S(-)-
sulpiride, SCH 23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-
phenyl-2,3 ,4,5 ,tetrahydro- lH-3-benzazepine; Biotrend, Co-
logrie, Germany) and quinpirole (LY 171555; Biotrend).
The following drugs were generous gifts: Carmoxirole (EMD
45609; Merck, Darmstadt, Germany); UK 14304 (5-bromo-6-[2-
imidazolin-2-ylamino]-quinoxaline; Pfizer, Karisruhe, Germa-
ny); fenoldopam (SKF 82526; Dr. Szabo, Pharmakologisches
Institut, Universitllt Freiburg, Germany); domperidone (Dr.
Limberger, Pharmakologisches Institut, Universität Freiburg);
idazoxan (Reckitt & Colman, Kingston-upon-Hull, UK). Phen-
tolamine, UK 14304 and tetrodotoxin were dissolved in distilled
water before being diluted with Krebs-Henseleit solution.
Fenoldopam, quinpirole, S(-)-sulpiride, domperidone and SCH
23390 were dissolved in 0.1 M tartaric acid before being diluted
in Krebs-Henseleit solution. Carmoxirole and corticosterone
were dissolved in absolute ethanol before being diluted with
Krebs-Henseleit solution. The respective vehicles had no effect
on the release of radioactivity, and control experiments with the
vehicles without drugs were combined.
Results
Human cortical kidney slices (mean wet wt 20.0 0.4 mg,
N 198) were incubated with 3H-noradrenaline and superfused
with Krebs-Henseleit solution in superfusion chambers be-
tween two platinum electrodes. The slices accumulated radio-
activity (132000 4200 dpmlmg, N = 198). Tissue levels of
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Table 1. Effect of drugs on the spontaneous (resting) outflow of
radioactivity in human kidney slices preincubated with 3H-
noradrenaline
Drug treatment R2/R1 % N
Control 87.3 0.9 20
Ca'-free 89.8 1.6 5
rFX (1 LM) 84.4 1.1 5
SKF (0.01 jsM) 86.1 1.9 4
SKF (0.1 !sM) 87.0 4.3 5
SKF (1 M) 86.3 1.4 8
QUI (1 &M) 86.7 3.3 5
UK 14304 (0.1 sM) 81.7 2.l 5
EMD (0.003 M) 86.5 2.4 5
EMD (0.03 tM) 84.9 1.4 6
EMD (0.3 LM) 89.1 2.2 5
SCH (1 JLM) 85.1 1.2 5
SUL (10 /LM) 89.4 1.6 5
DOM (0.3 M) 100.2 1,oa 4
IDA (1 ILM) 86.7 1.6 3
PHE(1M) 85.0±1.2 6
There were two stimulation periods (S1 and S2), 27 minutes apart, at
5 Hz for 60 seconds. Drugs were added 12 minutes before S2. Results
are expressed as R2 (resting outflow of radioactivity during S2) as a
percentage of R1 (resting outflow of radioactivity during S1). Drug
treatments: Ca-free, tetrodotoxin (TFX), fenoldopam (SKF), quin-
pirole (QUI), UK 14304, carmoxirole (EMD), S(-)-sulpiride (SUL),
SCH 23390 (SCH), domperidone (DOM), idazoxan (IDA) and phentol-
amine (PHE). All data are mean SEM.
a Significant effect of drug treatment as compared to control (Stu-
dent's t test, P < 0.05)
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Fig. 1. Effect of tetrodotoxin (TTX, I i) and omission of Ca on the
S-I outflow of radioactivity from human kidney slices preincubated with
3H-noradrenaline. The slices were superfused with Krebs-Henseleit
solution in superfusion chambers and 17 consecutive 3-minute fractions
of the superfusate were collected. There were two stimulation periods
(S1 and S2), 6 and 33 minutes after commencement of the collections,
each at 5 Hz for 60 seconds, respectively. The amount of radioactivity
present in each 3 minute sample is expressed as a fraction of the total
tissue radioactivity at the time of the collection. TTX was added to or
Ca was omitted from the superfusion solution 12 minutes before S2.
All data are means SEM for each set of experiments: Control (N = 20,
circles), TFX (N = 5, squares) and omission of Ca (N = 5, triangles).
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endogenous noradrenaline were 308 45 ng/g (N 11). There
were two electrical field stimulations (S1 and S2) and the
fractional S-I outflow of radioactivity in S1 was 1.13 0.05% of
the total tissue radioactivity. In some experiments the superfu-
sate samples were assayed for their 3H-noradrenaline content.
Unmetabolized 3H-noradrenaline accounted for 62.8 1.4%
(N = 4) of the S-I outflow of radioactivity. In contrast, the
spontaneous (resting) outflow of radioactivity contained only 3
1% (N = 4) unmetabolized 3H-noradrenaline. The effect of
drugs on the spontaneous outflow of radioactivity is shown in
Table 1.
Effects of tetrodotoxin, omission of Ca and 6-hydroxy-
dopamine on S-I outflow of radioactivity
In control experiments S-I outflow of radioactivity was
similar in both stimulation periods (Fig. 1). The sodium channel
blocker tetrodotoxin (1 pM), added to the superfusion solution
12 minutes before 52, and omission of Ca + abolished S-I
outflow of radioactivity (Fig. 1). In vitro pretreatment of the
tissue with 6-hydroxydopamine (1.2 mM) prior to incubation
with 3H-noradrenaline markedly reduced total tissue radioac-
tivity and abolished S-I outflow of radioactivity (Fig. 2).
Effects of quinpirole, fenoldopam and UK 14304 on S-I
outflow of radioactivity
The DA2-receptor agonist quinpirole (1 M) inhibited S-I
outflow of radioactivity (Fig. 3). This inhibitory effect was
neither altered by the DA1-receptor antagonist SCH 23390 (1
/sM) nor by the non-selective cl-adrenoceptor antagonist phen-
tolamine (1 /xM; Fig. 3). However, the DA2-receptor antagonists
S(-)-sulpiride (10 LM) and domperidone (0.3 jsM) abolished the
inhibitory effect of quinpirole (Fig. 3). The a2-adrenoceptor
agonist UK 14304 (0.1 xM) inhibited S-I outflow of radioactiv-
ity, and this inhibitory effect was blocked by phentolamine (1
ELM) and the selective a2-adrenoceptor antagonist idazoxan (1
/LM), but unaltered by S(-)-sulpiride (10 .rtv1; Fig. 4). The
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Fig. 2. Effect of 6-hydroxy-dopamine (6-OH-
DA) pretreatment on accumulation of tissue
radioactivity and S-I outflow of radioactivity
in human kidney slices preincubated with 3H-
noradrenaline, Prior to incubation with 3H-
noradrenaline the slices were either pretreated
with 6-OH-DA (0, 1.2 mi, N =4) or vehicle(•, N = 4) for 10 minutes. After incubation
with 3H-noradrenaline the slices were
superfused with Krebs-Henseleit solution in
superfusion chambers. Seventeen consecutive
3 minute fractions of the superfusate were
collected. There were two stimulation periods
(S1 and S,), 6 and 33 minutes after
commencement of the collections, each at 5
Hz for 60 seconds, respectively. The amount
of radioactivity present in each 3 minute
sample is expressed as a fraction of the total
tissue radioactivity at the time of the
collection. * Indicates significant difference
from corresponding control (Student's t-test,
P < 0.05).
Fig. 3. Effect of quinpirole (QUI) on the
fractional S-I outflow of radioactivity in
human kidney slices preincubated with iii-
noradrenaline. There were two stimulation
periods (S1 and S2), 27 minutes apart, each at
5 Hz for 60 seconds. QUI was added 12
minutes before There were five sets of
experiments: (1.) In the absence of other
drugs: control (CON, N = 20), QUI (1 LM, N
= 5). (2.) Phentolamine (PHE) present for
both stimulation periods (th): control (CON,
N = 9), QUI (1 /.LM, N = 5). (3.)
Domperidone (DOM) present for both
stimulation periods (th): CON (N = 4), QUI(0.3 M, N = 4). (4.) S(-)-sulpiride ((-)-SUL)
present for both stimulation periods: CON (N
= 5), QUI (1 LM, N = 5). (5.) SCH 23390
present for both stimulation periods (th): CON(N = 6) and QUI (1 sM, N = 5). All data are
means SEM. * Indicates significant
difference from corresponding control
(Student's t-test, P < 0.05).
DA1-receptor agonist fenoldopam (0.01 and 0.1 tM) did not
alter, but fenoldopam (1 jIM) enhanced S-I outflow of radioac-
tivity (Fig. 5). However, the facilitatory effect of fenoldopam (1
tLM) was not observed in the presence of either phentolamine (1
M) or idazoxan (1 jiM; Fig. 5). None of the drugs altered the
spontaneous outflow of radioactivity except UK 14304, which
slightly decreased the spontaneous outflow of radioactivity
(Table 1).
Effect of carmoxirole on S-I outflow of radioactivity
The DA2-receptor agonist carmoxirole (0.03 jiM) inhibited S-I
outflow of radioactivity (Fig. 6). However, carmoxirole (0.003
and 0.3 jiM) failed to alter S-I outflow of radioactivity. In the
presence of phentolamine (1 jiM) carmoxirole (0.03 and 0.3 jiM)
inhibited S-I outflow of radioactivity to a similar extent. More-
over, carmoxirole (0.3 jiM) also inhibited S-I outflow of radio-
activity in the presence of idazoxan (1 jiM). The inhibitory
effect of carmoxirole (0.03 jiM) was not altered by SCH 23390(1
jiM) but was abolished by S(-)-suipiride (10 jiM; Fig. 6).
Carmoxirole (0.003 to 0.3 jiM) had no effect on the spontaneous
outflow of radioactivity (Table 1).
Effects of S(-)-sulpiride, domperidone, SCH 23390,
phentolamine and idazoxan on S-I outflow of radioactivity
S(-)-sulpiride (10 jiM), domperidone (0.3 jiM) and SCH 23390
(1 jiM), given to the superfusion solution 12 minutes before S2,
had no effect on the S-I outflow of radioactivity (Fig. 7).
However, phentolamine (1 jiM) and idazoxan (1 jiM) enhanced
S-I outflow of radioactivity (Fig. 7). S(-)-sulpiride, SCH 23390
and phentolamine had no effect on the spontaneous outflow of
radioactivity (Table 1). Domperidone slightly increased the
spontaneous outflow of radioactivity (Table 1).
Discussion
In the present study human renal cortex slices were incu-
bated with 3H-noradrenaline and superfused with Krebs-Hense-
leit solution. The renal cortex slices accumulated radioactivity.
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Fig. 4. Effect of UK 14304 (UK) on the fractional S-I outflow of
radioactivity in human kidney slices preincubated with 3H-noradrena-
line. There were two stimulation periods (S1 and S2), 27 minutes apart,
each at 5 Hz for 60 seconds. UK was added 12 minutes before S2. There
were four sets of experiments: (1.) In the absence of other drugs:
control (CON, N = 20), UK (0.1 sM, N = 5). (2.) Phentolamine (PHE)
present for both stimulation periods (th): CON (N = 9), UK (N = 5).
(3.) Idazoxan (IDA) present for both stimulation periods (th): CON (N
= 6), UK (0.1 sM, N = 4), (4.) S(-)-sulpiride ((-)-SUL) present for both
stimulation periods (th): CON (N = 5), UK (0.1 sM, N 4). All data are
means SEM. * Indicates significant difference from corresponding
control (Student's t-test, P < 0.05).
The accumulation and storage of radioactivity was dependent
on intact sympathetic nerves since it was markedly reduced by
pretreatment of the slices with 6-hydroxydopamine, which is
known to destroy sympathetic nerve terminals [30]. Tissue
levels of endogenous noradrenaline in the human renal cortex
were comparable to those measured previously in the rat kidney
[31, 32]. The S-I outflow of radioactivity was prevented by the
sodium channel blocker tetrodotoxin and by omission of cal-
cium from the superfusion solution. Influx of extracellular
calcium [33] and the arrival of action potentials at the nerve
terminals, which can be prevented by tetrodotoxin [34], are
necessary requirements for the exocytotic release of noradren-
aline. Previous studies have shown that the S-I outflow of
radioactivity from sympathetically innervated tissues incubated
with 3H-noradrenaline is to a large extent composed of unme-
tabolized 3H-noradrenaline, whereas the spontaneous outflow
of radioactivity is mainly composed of 3H-metabolites [2, 35].
Similar results were obtained in the present study. Thus, the
superfused cortical kidney slice is a valid technique to study
modulation of noradrenaline release from human renal sympa-
thetic nerves in vitro. In the present study the DA1-receptor
agonist fenoldopam [36, 37] in low concentrations (0.01 and 0.1
p,M) did not alter S-I outflow of radioactivity, but in a high
concentration (1 LM) enhanced it. Fenoldopam has been shown
to stimulate cyclic-adenosine-monophosphate (cAMP) forma-
tion in human renal cortex [38], and cAMP analogues as the
cell-permeable 8-bromo-cAMP enhance noradrenaline release
in mouse atria [39] and rat renal cortex [40]. However, the
facilitatory effect of fenoldopam (1 M) was not observed in
either the presence of phentolamine or idazoxan, and therefore
does not appear to be due to activation of DA1-receptors and
cAMP formation. Another explanation seems to be more likely.
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Fig. 5. Effect of fenoldopam (SKF) on the fractional S-i outflow of
radioactivity in human kidney slices preincubated with 3H-noradrena-
line. There were two stimulation periods (S1 and S2), 27 minutes apart,
each at 5 Hz for 60 seconds. SKF was added 12 minutes before S2.
There were three sets of experiments: (I.) In the absence of other drugs:
control (CON, N = 20), SKF (0.01 tM, N = 4), SKF (0.1 rM, N = 5),
SKF (I rM, N = 8). (2.) Phentolamine (PHE) present for both
stimulation periods (th): CON (N = 9), SKF (1 sM, N = 8). (3.)
Idazoxan (IDA) present for both stimulation periods (th): CON (N = 6),
SKF (1 /SM, N = 4). All data are means SEM. * Indicates significant
difference from corresponding control (Student's t-test, P < 0.05).
Drugs can enhance S-I outflow of radioactivity from tissues
labeled with 3H-noradrenaline indirectly by blocking inhibitory
prejunctional a-autoreceptors [41]. Fenoldopam has been
shown to possess a2-adrenoceptor antagonist activity [42, 43],
and the selective a2-adrenoceptor antagonist idazoxan as well
as the non-selective a-adrenoceptor antagonist phentolamine
enhanced S-I outflow in the present study. Thus, when prejunc-
tional a-adrenoceptors were already blocked by either phentol-
amine or idazoxan (present throughout the whole experiment),
fenoldopam (1 rM) failed to enhance S-I outflow of radioactiv-
ity. This strongly suggests that the faciitatory effect of fenol-
dopam is due to blockade of inhibitory prejunctional a-autore-
ceptor in human renal cortex. Our findings are in accord with a
study in the rat superior mesenteric vascular bed [441, in which
fenoldopam enhances stimulation induced pressor responses
due to increased neuronal noradrenaline release, but inhibits
pressor responses to exogenously applied noradrenaline due to
DA1-receptor mediated vasorelaxation.
The DA2-receptor agonist quinpirole [45] inhibited S-I out-
flow of radioactivity, and this effect was blocked by the
DA2-receptor antagonists S(-)-sulpiride [46] and dompendone
[47], but not by the DA1-receptor antagonist SCH 23390 [48].
This suggests that in human kidney cortex, as in rat and rabbit
isolated kidney [5—7], activation of prejunctional DA2-receptors
inhibits noradrenaline release. There may be another explana-
tion. Quinpirole in a concentration of I M has been shown to
activate prejunctional a2-adrenoceptors in the rat pituitary
gland [49]. Prejunctional inhibitory a2-adrenoceptors seem also
to be present in human renal cortex, since the a2-adrenoceptor
agonist UK 14304 [50] inhibited S-I outflow of radioactivity, and
its inhibitory effect was blocked by the a2-adrenoceptor antag-
onist idazoxan and the non-selective a-adrenoceptor antagonist
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Fig. 6. Effect of carmoxirole (EMD) on the
fractional S-I outflow of radioactivity in
human kidney slices preincubated with 3H-
noradrenaline. There were two stimulation
periods (S1 and S2), 27 minutes apart, each at
5 Hz for 60 seconds. EMD was added 12
minutes before S2. There were five sets of
experiments: (1.) In the absence of other
drugs: control (CON, N = 20), EMD (0.003
/SM, N = 5), EMD (0.03 LM, N = 6), EMD(0.3 M, N = 6). (2.) Phentolamine (PHE)
present for both stimulation periods (th): CON
(N = 9), EMD (0.03 M, N = 5), EMD (0.3
JIM, N = 5). (3.) Idazoxan (IDA) present for
both stimulation periods (th): CON (N = 6),
EMD (0.3 JIM, N 4). (4.) S().sulpiride ((-)-
SUL) present for both stimulation periods
(th): CON (N = 5), EMD (0.03 M, N = 5).
(5.) SCH 23390 present for both stimulation
periods (th): CON (N = 6), EMD (0.03 sM, N
= 6). All data are means SEM. * Indicates
significant difference from corresponding
control (Student's t-test, P < 0.05).
Fig. 7. Effects of SCH 23390 (SCH), S(-)-sulpiride (SUL), domperi-
done (DOM), phentolamine (PHE) and idazoxan (IDA) on the frac-
tional S-I outflow of radioactivity in human kidney slices preincubated
with 3H-noradrenaline. There were two stimulation periods (S1 and S2),
27 minutes apart, each at 5 Hz for 60 seconds. Drugs were added 12
minutes before S2. Control (CON, N = 20), SCH (1 sM, N = 5), SUL(10 M, N = 5), DOM (0.3 M, N = 4), PHE (1 M, N =6) and IDA(N = 3). All data are means SEM. * Indicates significant difference
from control (Student's t-test, P < 0.05).
phentolamine. However, the inhibitory effect of quinpirole, in
contrast to that of UK 14304, is not due to an effect on
prejunctional a-adrenoceptors, since it was not altered by
phentolamine. Moreover, S(-)-sulpiride, which abolished the
inhibitory effect of quinpirole, failed to alter the inhibitory effect
of UK 14304.
Carmoxirole is a recently developed DA2-receptor agonist,
which does not readily penetrate into the central nervous
system [211. It has been shown to inhibit noradrenaline release
in the rabbit ear artery [51]. In the present study in human renal
cortex carmoxirole (0.03 /LM) inhibited S-I outflow of radioac-
tivity; this inhibitory effect was blocked by S(-)-sulpiride but
not by SCH 23390. This suggests that carmoxirole activates
prejunctional DA2-receptors on sympathetic nerve endings in
human renal cortex to inhibit noradrenaline release. However,
a ten times higher concentration of carmoxirole (0.3 tM) failed
to inhibit S-I outflow of radioactivity. Many dopaminergic drugs
interact with prejunctional inhibitory a-autoreceptors [9].
Therefore, the effect of carmoxirole (0.3 FM) was tested in the
presence of a-adrenoceptor blockade by either phentolamine or
idazoxan. And indeed, in this situation carmoxirole (0.3 LM)
inhibited S-I outflow of radioactivity. In the presence of phen-
tolamine carmoxirole (0.3 xM) and carmoxirole (0.03 p.M)
inhibited S-I outflow of radioactivity to a similar extent. Thus,
at a stimulation frequency of 5 Hz in human renal cortex the
maximal inhibitory effect of carmoxirole seems to be reached at
a concentration of 0.03 p.M. At higher concentrations this
inhibitory DA2-receptor mediated effect of carmoxirole seems
to be counteracted by simultaneous blockade of prejunctional
a-autoreceptors. A similar concentration dependent effect of
carmoxirole has recently been observed in rat isolated kidney
[52].
There is morphological, biochemical and some functional
evidence that the kidney may receive a dopaminergic innerva-
tion [53]. Whether or not these dopaminergic nerve fibers have
a physiological role is a matter of debate [54]. If electrical
stimulation of dopaminergic nerve fibers releases dopamine,
then one would expect that the blockade of prejunctional
dopamine receptors enhances noradrenaline release. However,
in the present study in human renal cortex, at a stimulation
frequency of 5 Hz S(-)-sulpiride, domperidone or SCH 23390
did not enhance S-I outflow of radioactivity. Thus, from our
study and previous in vitro data in isolated rat kidney [6, 7],
there is no evidence that endogenous dopamine activates
prejunctional inhibitory DA2-receptors,
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